| STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes |
|
Neoplasia |
Myelodysplastic Syndromes (MDS) |
| Clonal Selection and Evolution after Treatment of Severe Aplastic Anemia |
|
NEJM Evid |
Aplastic Anemia |
| Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag |
|
NEJM Evid |
Aplastic Anemia |
| Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes |
|
Nature Medicine |
Myelodysplastic Syndromes (MDS) |
| High-resolution single-cell mapping of clonal hematopoiesis and structural variation in aplastic anemia |
|
Nature Genetics |
Aplastic Anemia |
| Myelodysplastic Syndromes Treatment (PDQ®): Patient Version |
|
National Cancer Institute |
Myelodysplastic Syndromes (MDS) |
| TERC haploid cell reprogramming: a novel therapeutic strategy for aplastic anemia |
|
Molecular Medicine |
Aplastic Anemia |
| Haploidentical Transplant with Post-Transplant Cyclophosphamide for Acute Myeloid Leukaemia and Myelodysplastic Syndromes Patients: The Role of Previous Lines of Therapy |
|
Mediterranean Journal of Hematology and Infectious Diseases |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Observational and Genetic Association of Myelodysplastic Syndromes (MDS) and Autoimmune Diseases in Adults |
|
Mediators of Inflammation |
Myelodysplastic Syndromes (MDS) |
| Rewriting the rules for care of MDS and AML patients in the time of COVID-19 |
|
Leukemia Research Reports |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
